Fifth Third Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Fifth Third Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$999K	Buy	1,911 +62	+3%	+$31.7K	0.03%	317
2026 Q2	$918K	Sell	1,849 -280	-13%	-$124K	0.03%	318
2026 Q1	$951K	Buy	2,129 +415	+24%	+$194K	0.03%	282
2025 Q4	$777K	Sell	1,714 -86	-5%	-$37.1K	0.03%	298
2025 Q3	$705K	Sell	1,800 -26	-1%	-$10.9K	0.03%	301
2025 Q2	$813K	Sell	1,826 -8	-0.4%	-$3.69K	0.03%	275
2025 Q1	$889K	Buy	1,834 +607	+49%	+$283K	0.05%	240
2024 Q4	$494K	Buy	1,227 +230	+23%	+$107K	0.03%	336
2024 Q3	$464K	Buy	997 +489	+96%	+$235K	0.03%	327
2024 Q2	$238K	Buy	+508	New	+$220K	0.02%	519

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Fifth Third Wealth Advisors's VRTX Position: Q3 2026 in Review

Fifth Third Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q3 2026, buying an estimated $31.7K and bringing the position to 1,911 shares worth $999K. The position accounts for 0.03% of the portfolio, ranked #317.

Fifth Third Wealth Advisors first reported a position in VRTX in Q2 2024 and has held it in 10 quarters since. 439 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Fifth Third Wealth Advisors held 1,911 shares of Vertex Pharmaceuticals worth $999K as of Q3 2026.
Fifth Third Wealth Advisors bought 62 Vertex Pharmaceuticals shares in Q3 2026, an estimated $31.7K.
Vertex Pharmaceuticals made up 0.03% of Fifth Third Wealth Advisors's portfolio in Q3 2026, its #317 holding.
Fifth Third Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.